Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 HAIC OPC-18 + 5-FU vs Best Salvage Therapy in Advanced Hepatocellular Carcinoma
jRCT2080220441Phase 2
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2007
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Natural human interferon alfa, fluorouracil and interferon alfa-n1 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd.
02
Drugs
Natural human interferon alfafluorouracilinterferon alfa-n1
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080220441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220441.